Ibuprofen suppresses interleukin-Iβ induction of pro-amyloidogenic α1-antichymotrypsin to ameliorate β-amyloid (aβ) pathology in Alzheimer's models

Neuropsychopharmacology

Volumn 30, Issue 6, 2005, Pages 1111-1120

  Morihara, Takashi ^a,c,e   Teter, Bruce ^a,c   Yang, Fusheng ^a,c   Lim, Giselle P ^a,c   Boudinot, Sally ^b   Boudinot, F Douglas ^b   Frautschy, Sally A ^a,c,d   Cole, Greg M ^a,c,d  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

APP transgenic mice (Tg2576); Inflammation; Nonsteroidal anti inflammatory drugs (NSAIDs)

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BETA SECRETASE; IBUPROFEN; INTERLEUKIN 1BETA; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT;

ACUTE-PHASE PROTEINS; ALPHA 1-ANTICHYMOTRYPSIN; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; AMYLOIDOSIS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOLIPOPROTEINS E; ASPARTIC ENDOPEPTIDASES; ASTROCYTES; ASTROCYTOMA; BLOTTING, WESTERN; ENDOPEPTIDASES; IBUPROFEN; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1; MALE; MICE; MICE, TRANSGENIC; NEUROGLIA; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENILE PLAQUES; SERINE PROTEINASE INHIBITORS; TUMOR CELLS, CULTURED;

EID: 19344361883     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300668     Document Type: Article

References (80)

1. Abraham CR, Selkoe DJ, Potter H (1988). Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52: 487-501.
2. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM et al (2000). Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421.
3. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M et al (1997). Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 17: 263-264.
4. Breitner JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ et al (1994). Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 44: 227-232.
5. Bullido MJ, Artiga MJ, Recuero M, Sastre I, Garcia MA, Aldudo J et al (1998). A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet 18: 69-71.
6. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL et al (2001). BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 4: 233-234.
7. Das S, Potter H (1995). Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1. Neuron 14: 447-456.
8. Davies NM (1998). Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 34: 101-154.
9. Diedrich JF, Minnigan H, Carp RI, Whitaker JN, Race R, Frey II W et al (1991). Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J Virol 65: 4759-4768.
10. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC et al (2003). NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 112: 440-449.
11. Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM (2002). Related articles, links abstract human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis 9: 305-318.
12. Ferrari RA, Ward SJ, Zobre CM, Van Liew DK, Perrone MH, Connell MJ et al (1990). Estimation of the in vivo effect of cyclooxygenase inhibitors on prostaglandin E2 levels in mouse brain. Eur J Pharmacol 179: 25-34.
13. Frautschy S, Sigel JJ, Harris-White ME, Chu T, Cole GM (1999). Methods for evaluating in vivo redent models for Alzheimer's disease. In: Timiras P, Sternberg H (eds). Methods in Brain Aging. Springer-Verlag: Berlin. pp 66-76.
14. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME et al (2001). Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 22: 993-1005.
15. Gitter BD, Boggs LN, May PC, Czilli DL, Carlson CD (2000). Regulation of cytokine secretion and amyloid precursor protein processing by proinflammatory amyloid beta (A beta). Ann N Y Acad Sci 917: 154-164.
16. Harigaya Y, Shoji M, Nakamura T, Matsubara E, Hosoda K, Hirai S (1995). Alpha 1-antichymotrypsin level in cerebrospinal fluid is closely associated with late onset Alzheimer's disease. Intern Med 34: 481-484.
17. in t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T et al (2001). Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345: 1515-1521.
18. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM et al (2002). Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22: 2246-2254.
19. Kannan S, Kolhe P, Raykova V, Glibatec M, Kannan RM, Lieh-Lai M et al (2004). Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells. J Biomater Sci Polym Ed 15: 311-330.
20. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001). Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21: 372-381.
21. Koo EH, Abraham CR, Potter H, Cork LC, Price DL (1991). Developmental expression of alpha 1-antichymotrypsin in brain may be related to astrogliosis. Neurobiol Aging 12: 495-501.
22. Kordula T, Bugno M, Rydel RE, Travis J (2000). Mechanism of interleukin-1- and tumor necrosis factor alpha-dependent regulation of the alpha 1-antichymotrypsin gene in human astrocytes. J Neurosci 20: 7510-7516.
23. Lambert JC, Pasquier F, Cottel D, Frigard B, Amouyel P, Chartier-Harlin MC (1998). A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Hum Mol Genet 7: 533-540.
24. Lambert JC, Perez-Tur J, Dupire MJ, Galasko D, Mann D, Amouyel P et al (1997). Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. Hum Mol Genet 6: 2151-2154.
25. Laping NJ, Morgan TE, Nichols NR, Rozovsky I, Young-Chan CS, Zarow C et al (1994a). Transforming growth factor-beta 1 induces neuronal and astrocyte genes: tubulin alpha 1, glial fibrillary acidic protein and clusterin. Neuroscience 58: 563-572.
26. Laping NJ, Teter B, Nichols NR, Rozovsky I, Finch CE (1994b). Glial fibrillary acidic protein: regulation by hormones, cytokines, and growth factors. Brain Pathol 4: 259-275.
27. Laws SM, Taddei K, Martins G, Paton A, Fisher C, Clarnette R et al (1999). The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease. NeuroReport 10: 879-882.
28. Licastro F, Mallory M, Hansen LA, Masliah E (1998). Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype. J Neuroimmunol 88: 105-110.
29. Licastro F, Parnetti L, Morini MC, Davis LJ, Cucinotta D, Gaiti A et al (1995). Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease. Alzheimer Dis Assoc Disord 9: 112-118.
30. Licastro F, Pedrini S, Ferri C, Casadei V, Govoni M, Pession A et al (2000). Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann Neurol 48: 388-391.
31. Lieb K, Fiebich BL, Schaller H, Berger M, Bauer J (1996). Interleukin-1 beta and tumor necrosis factor-alpha induce expression of alpha 1-antichymotrypsin in human astrocytoma cells by activation of nuclear factor-kappa B. J Neurochem 67: 2039-2044.
32. Lieberman J, Schleissner L, Tachiki KH, Kling AS (1995). Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia. Neurobiol Aging 16: 747-753.
33. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B et al (2000). Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20: 5709-5714.
34. Lim GP, Yang F, Chu T, Gahtan E, Ubeda O, Beech W et al (2001). Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 22: 983-991.
35. Lo CJ, Cryer HG, Fu M, Lo FR (1998). Regulation of macrophage eicosanoid generation is dependent on nuclear factor kappaB. J Trauma 45: 19-23 ; discussion 23-14.
36. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P et al (2001). Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4: 231-232.
37. Ma J, Yee A, Brewer Jr HB, Das S, Potter H (1994). Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372: 92-94.
38. Martin BK, Meinert CL, Breitner JC (2002). Double placebo design in a prevention trial for Alzheimer's disease. Control Clin Trials 23: 93-99.
39. Matsubara E, Hirai S, Amari M, Shoji M, Yamaguchi H, Okamoto K et al (1990). Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann Neurol 28: 561-567.
40. McCarthy KD, de Vellis J (1980). Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85: 890-902.
41. McGeer EG, McGeer PL (2003). Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 27: 741-749.
42. McGeer PL, Schulzer M, McGeer EG (1996). Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47: 425-432.
43. Morihara T, Chu T, Ubeda O, Beech W, Cole GM (2002). Selective inhibition of Abeta42 production by NSAID R-enantiomers. J Neurochem 83: 1009-1012.
44. Mrak RE, Griffin WS (2000). Interleukin-1 and the immunogenetics of Alzheimer disease. J Neuropathol Exp Neurol 59: 471-476.
45. Mrak RE, Griffin WS (2001). Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging 22: 903-908.
46. Mucke L, Yu GQ, McConlogue L, Rockenstein EM, Abraham CR, Masliah E (2000). Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice. Am J Pathol 157: 2003-2010.
47. Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S et al (2000). Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 47: 365-368.
48. Nilsson LN, Bales KR, DiCarlo G, Gordon MN, Morgan D, Paul SM et al (2001). Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J Neurosci 21: 1444-1451.
49. Pahnke J, Walker LC, Schroeder E, Vogelgesang S, Stausske D, Walther R et al (2003). Cerebral beta-amyloid deposition is augmented by the -491AA promoter polymorphism in non-demented elderly individuals bearing the apolipoprotein E epsilon4 allele. Acta Neuropathol (Berl) 105: 25-29.
50. Pasternack JM, Abraham CR, Van Dyke BJ, Potter H, Younkin SG (1989). Astrocytes in Alzheimer's disease gray matter express alpha 1-antichymotrypsin mRNA. Am J Pathol 135: 827-834.
51. Petegnief V, Saura J, de Gregorio-Rocasolano N, Paul SM (2001). Neuronal injury-induced expression and release of apolipoprotein E in mixed neuron/glia co-cultures: nuclear factor kappaB inhibitors reduce basal and lesion-induced secretion of apolipoprotein E. Neuroscience 104: 223-234.
52. Poirier J, Hess M, May PC, Finch CE (1991). Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Brain Res Mol Brain Res 11: 97-106.
53. Qiao X, Cummins DJ, Paul SM (2001). Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse. Eur J Neurosci 14: 474-482.
54. Qin W, Ho L, Pompl PN, Peng Y, Zhao Z, Xiang Z et al (2003). Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. J Biol Chem 278: 50970-50977.
55. Quinn J, Montine T, Morrow J, Woodward WR, Kulhanek D, Eckenstein F (2003). Related articles, links abstract inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J Neuroimmunol 137: 32-41.
56. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS et al (2001). BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 10: 1317-1324.
57. Roks G, Cruts M, Bullido MJ, Backhovens H, Artiga MJ, Hofman A et al (1998). The -491 A/T polymorphism in the regulatory region of the apolipoprotein E gene and early-onset Alzheimer's disease. Neurosci Lett 258: 65-68.
58. Sagi SA, Weggen S, Eriksen J, Golde TE, Koo EH (2003). The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. J Biol Chem 278: 31825-31830.
59. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F et al (2003). Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23: 9796-9804.
60. Schauwecker PE, Cogen JP, Jiang T, Cheng HW, Collier TJ, McNeill TH (1998). Differential regulation of astrocytic mRNAs in the rat striatum after lesions of the cortex or substantia nigra. Exp Neurol 149: 87-96.
61. Shao Y, Gearing M, Mirra SS (1997). Astrocyte-apolipoprotein E associations in senile plaques in Alzheimer disease and vascular lesions: a regional immunohistochemical study. J Neuropathol Exp Neurol 56: 376-381.
62. Shoji M, Hirai S, Yamaguchi H, Harigaya Y, Ishiguro K, Matsubara E (1991). Alpha 1-antichymotrypsin is present in diffuse senile plaques. A comparative study of beta-protein and alpha 1-antichymotrypsin immunostaining in the Alzheimer brain. Am J Pathol 138: 247-257.
63. Song YQ, Rogaeva E, Premkumar S, Brindle N, Kawarai T, Orlacchio A et al (1998). Absence of association between Alzheimer disease and the -491 regulatory region polymorphism of APOE. Neurosci Lett 250: 189-192.
64. Soulie C, Mitchell V, Dupont-Wallois L, Chartier-Harlin MC, Beauvillain JC, Delacourte A et al (1999). Synthesis of apolipoprotein E (ApoE) mRNA by human neuronal-type SK N SH-SY 5Y cells and its regulation by nerve growth factor and ApoE. Neurosci Lett 265: 147-150.
65. Stewart WF, Kawas C, Corrada M, Metter EJ (1997). Risk of Alzheimer's disease and duration of NSAID use. Neurology 48: 626-632.
66. Takahashi Y, Hayashi I, Tominari Y, Rikimaru K, Morohashi Y, Kan T et al (2003). Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J Biol Chem 278: 18664-18670.
67. Tegeder I, Pfeilschifter J, Geisslinger G (2001). Cyclooxygenase- independent actions of cyclooxygenase inhibitors. FASEB J 15: 2057-2072.
68. Wang X, DeKosky ST, Ikonomovic MD, Kamboh MI (2002a). Distribution of plasma alpha 1-antichymotrypsin levels in Alzheimer disease patients and controls and their genetic controls. Neurobiol Aging 23: 377-382.
69. Wang X, DeKosky ST, Luedecking-Zimmer E, Ganguli M, Kamboh IM (2002b). Genetic variation in alpha(1)-antichymotrypsin and its association with Alzheimer's disease. Hum Genet 110: 356-365.
70. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU et al (2001). A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414: 212-216.
71. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH (2003a). Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 278: 30748-30754.
72. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A et al (2003b). Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem 278: 31831-31837.
73. Xiang Z, Ho L, Valdellon J, Borchelt D, Kelley K, Spielman L et al (2002). Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging 23: 327-334.
74. Yamada T, Kondo A, Takamatsu J, Tateishi J, Goto I (1995). Apolipoprotein E mRNA in the brains of patients with Alzheimer's disease. J Neurol Sci 129: 56-61.
75. Yamauchi K, Tozuka M, Hidaka E, Ueno I, Matsuda K, Katsuyama T (2003). Internalization of beta-amyloid causes downregulation of apolipoprotein E mRNA expression in neuroblastoma cells. Ann Clin Lab Sci 33: 68-78.
76. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL et al (2003). Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23: 7504-7509.
77. Yasojima K, Schwab C, McGeer EG, McGeer PL (1999). Upregulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol 154: 927-936.
78. Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC (2002). Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 59: 880-886.
79. Zarow C, Victoroff J (1998). Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning. Exp Neurol 149: 79-86.
80. Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X et al (2003). Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 302: 1215-1217.